PYXS Pyxis Oncology, Inc.

NASDAQ
$2.86

Pyxis Oncology, Inc. (PYXS) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.1% since its last earnings release on August 13, 2026.

Pyxis Oncology Missed Consensus Estimates
Thursday, August 13, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.27)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Pyxis Oncology, Inc.

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.